The effectiveness of “Firocoxib” in the complex palliative treatment of soft tissue sarcomas in dogs
https://doi.org/10.32634/0869-8155-2025-396-07-14-22
Abstract
The article presents the results of long-term use of “Firocoxib” for the treatment and control of the inflammatory process in animals with a confirmed diagnosis of soft tissue sarcoma of an indeterminate phenotype in the head area. The study was conducted in 2024–2025 on the basis of the Department of Diseases of Small Domestic, Laboratory and Exotic Animals of the Russian Biotechnological University (Rosbiotech). The object of the study was 40 dogs with unresectable soft tissue sarcomas of an indeterminate phenotype in the head region, confirmed histologically.
The aim of the work was to study the effect of “Firocoxib” in the complex therapy of unresectable soft tissue sarcomas with an assessment of the course of the local inflammatory process. During the study, 4 groups of dogs were formed, in which the volume of the affected tissue, the degree of inflammation, pain syndrome and the growth rate of unresectable malignant neoplasms in dogs were determined. “Firocoxib” was used in three groups as a nonsteroidal anti-inflammatory drug in combination with “Carboplatin” (an alkylating antineoplastic drug), the fourth group served as a control (“Carboplatin” was used in monotherapy for animals in this group).
According to the results of the study, “Firocoxib” reduced the inflammatory component and the degree of pain in the area of localization of the oncological process, which significantly improved the quality of life in all three groups of dogs compared with the control, while no side effects were detected. “Firocoxib” has been shown to significantly enhance the antitumor activity of “Carboplatin” by relieving the inflammatory process and partially inhibiting tumor development, leading to partial remission and increased overall survival.
About the Authors
J. N. Melikova
Russian Biotechnological University (Rosbiotech)
Russian Federation
Russian Federation
Julia Nikolaevna Melikova, Candidate of Veterinary Sciences, Associate Professor of the Department of Diseases of Small Domestic, Laboratory and Exotic Animals
11 Volokolamskoye highway, Moscow, 125080
A. V. Chechneva
Russian Biotechnological University (Rosbiotech)
Russian Federation
Russian Federation
Anastasia Vyacheslavovna Chechneva, Candidate of Veterinary Sciences, Associate Professor of the Department of Diseases of Small Domestic, Laboratory and Exotic Animals
11 Volokolamskoye highway, Moscow, 125080
D. A. Vilmis
Russian Biotechnological University (Rosbiotech)
Russian Federation
Russian Federation
Darya Aleksandrovna Vilmis, Candidate of Veterinary Sciences, Associate Professor of the Department of Diseases of Small Domestic, Laboratory and Exotic Animals
11 Volokolamskoye highway, Moscow, 125080
U. A. Malyukova
Russian Biotechnological University (Rosbiotech)
Russian Federation
Russian Federation
Ulyana Andreevna Malyukova, Student
11 Volokolamskoye highway, Moscow, 125080
References
1. Lozovskaya E.A., Silkin I.I. Periodontoms of dogs and cats on the example of the City of Irkutsk. Science and education: experience, problems of development. Proceedings of the International scientific and practical conference. Krasnoyarsk: Krasnoyarsk State Agrarian University. 2020; 2: 332–335 (in Russian). https://www.elibrary.ru/ewgfgx
2. Kharyanova A.S., Dashko D.V. The prevalence of oncological diseases in dogs and cats of Irkutsk. Actual Problems of Veterinary Science and Practice. Collection of materials of the All-Russian (national) scientific and practical conference. Omsk: Omsk State Agrarian University named after P.A. Stolypin. 2021: 213–216 (in Russian). https://www.elibrary.ru/vuenam
3. Kamstock D.A., Russell D.S., Powers B.E. The Pathology of Neoplasia. Vail D.M., Thamm D.H., Liptak J.M. (eds.). Withrow & MacEwen’s Small Animal Clinical Oncology. 6th Edition. Elsevier. 2019; 61‒81.
4. Gustafson D.L., Bailey D.B. Cancer Chemotherapy. Vail D.M., Thamm D.H., Liptak J.M. (eds.). Withrow & MacEwen’s Small Animal Clinical Oncology. 6th Edition. Elsevier. 2019; 182‒205.
5. Liptak J.M., Christensen N.I. Soft Tissue Sarcomas. Vail D.M., Thamm D.H., Liptak J.M. (eds.). Withrow & MacEwen’s Small Animal Clinical Oncology. 6th Edition. Elsevier. 2019; 404‒431.
6. Melikova Yu.N., Chechneva A.V., Vernitskaya L.A. Cytoarchitectonics and morphofunctional parameters of dermal mastocytomas in the area of the facial skeleton in dogs. Agrarian science. 2025; (1): 50‒56 (in Russian). https://doi.org/10.32634/0869-8155-2025-390-01-50-56
7. Kulinsky V.I. Biochemical aspects of inflammation. Biochemistry (Moscow). 2007; 72(6): 595‒607. https://doi.org/10.1134/S0006297907060028
8. Sequeira I., Pires M.d.A., Leitão J., Henriques J., Viegas C., Requicha J. Feline Oral Squamous Cell Carcinoma: A Critical Review of Etiologic Factors. Veterinary Sciences. 2022; 9(10): 558. https://doi.org/10.3390/vetsci9100558
9. Kai F., Laklai H., Weaver V.M. Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease. Trends in Cell Biology. 2016; 26(7): 486‒497. https://doi.org/10.1016/j.tcb.2016.03.007
10. Cui J., Jia J. Natural COX-2 Inhibitors as Promising Antiinflammatory Agents: An Update. Current Medicinal Chemistry. 2021; 28(18): 3622‒3646. https://doi.org/10.2174/0929867327999200917150939
11. Aliabadi A., Khanniri E., Mahboubi-Rabbani M., Bayanati M. Dual COX-2/15-LOX inhibitors: A new avenue in the prevention of cancer. European Journal of Medicinal Chemistry. 2023; 261: 115866. https://doi.org/10.1016/j.ejmech.2023.115866
12. Rodrigues P. et al. COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers. Medical Oncology. 2024; 41: 41. https://doi.org/10.1007/s12032-023-02256-7
13. Gedon J., Kessler M., Schmidt J.M. Frontal sinus carcinoma in forty‐one dogs (2001–2022). Veterinary and Comparative Oncology. 2023; 21(2): 231‒239. https://doi.org/10.1111/vco.12880
14. Alonso‐Miguel D. et al. Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase‐2 inhibitor and toceranib phosphate. Veterinary and Comparative Oncology. 2022; 20(1): 179‒188. https://doi.org/10.1111/vco.12760
15. Mahboubi-Rabbani M., Abdolghaffari A.H., Ghesmati M., Amini A., Zarghi A. Selective COX-2 inhibitors as anticancer agents: a patent review (2018–2023). Expert Opinion on Therapeutic Patents. 2024; 34(9): 733‒757. https://doi.org/10.1080/13543776.2024.2373771
16. Doré M. Cyclooxygenase-2 expression in animal cancers. Veterinary pathology. 2011; 48(1): 254‒265. https://doi.org/10.1177/0300985810379434
17. Ching Lee C., Yang Soon Y., Nang Leong C., Yao Koh W., Tey J. Impact of programmed death-ligand 1 expression on the patients of stage IV non-small cell lung cancer harboring epidermal growth factor receptor mutation: a systematic review and meta-analysis. Acta Oncologica. 2020; 59(12): 1430–1437. https://doi.org/10.1080/0284186X.2020.1807600
18. Maekawa N. et al. Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. Scientific Reports. 2022; 12: 9265. https://doi.org/10.1038/s41598-022-13484-8
19. Brandi A. et al. Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors. Animals. 2023; 13(1): 60. https://doi.org/10.3390/ani13010060
20. Fuertes-Recuero M. et al. Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report. Veterinary Research Communications. 2024; 48(3): 1921‒1927. https://doi.org/10.1007/s11259-024-10349-5
21. Osada H. et al. Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma. Journal of Veterinary Medical Science. 2023; 85(9): 1004‒1009. https://doi.org/10.1292/jvms.22-0542
22. Beaudu-Lange C., Lange E. Intensive Multimodal Chemotherapy in a Dog Suffering from Grade III / Stage IV Solid Mammary Carcinoma. Animals. 2024; 14(17): 2618. https://doi.org/10.3390/ani14172618
23. Knapp D.W. et al. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. Journal of Veterinary Internal Medicine. 2013; 27(1): 126‒133. https://doi.org/10.1111/jvim.12013
24. Cancedda S. et al. Combination of radiation therapy and firocoxib for the treatment of canine nasal carcinoma. Veterinary Radiology & Ultrasound. 2015; 56(3): 335‒343. https://doi.org/10.1111/vru.12246
25. Fan V., Delport-Reynolds T., MacDonald-Dickinson V., Matsuyama A. Retrospective analysis of carboplatin-induced cumulative neutropenia in cancer-bearing dogs. Veterinary and comparative oncology. Journal of the American Veterinary Medical Association. 2024; 262(11): 1‒7. https://doi.org/10.2460/javma.24.02.0109
26. Pritchard C., Al-Nadaf S., Rebhun R.B., Willcox J.L., Skorupski K.A., Lejeune A. Efficacy and toxicity of carboplatin in the treatment of macroscopic mesenchymal neoplasia in dogs. Veterinary and Comparative Oncology. 2023; 21(4): 717‒725. https://doi.org/10.1111/vco.12936
Review
For citations:
Melikova J.N., Chechneva A.V., Vilmis D.A., Malyukova U.A. The effectiveness of “Firocoxib” in the complex palliative treatment of soft tissue sarcomas in dogs. Agrarian science. 2025;(7):14-22. (In Russ.) https://doi.org/10.32634/0869-8155-2025-396-07-14-22
Views:
33
Email this article 